Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Activation of the proapoptotic receptor death receptor5 (DR5) in various cancer cells triggers programmed cell death through the extrinsic pathway. We have generated a fully human monoclonal antibody (Apomab) that induces tumor cell apoptosis through DR5 and investigated the structural features of its interaction with DR5. Biochemical studies showed that Apomab binds DR5 tightly and selectively. X-ray crystallographic analysis of the complex between the Apomab Fab fragment and the DR5 ectodomain revealed an interaction epitope that partially overlaps with both regions of the Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand binding site. Apomab induced DR5 clustering at the cell surface and stimulated a death-inducing signaling complex containing the adaptor molecule Fas-associated death domain and the apoptosis-initiating protease caspase-8. Fc crosslinking further augmented Apomab's proapoptotic activity. In vitro, Apomab triggered apoptosis in cancer cells, while sparing normal hepatocytes even upon anti-Fc crosslinking. In vivo, Apomab exerted potent antitumor activity as a single agent or in combination with chemotherapy in xenograft models, including those based on colorectal, non-small cell lung and pancreatic cancer cell lines. These results provide structural and functional insight into the interaction of Apomab with DR5 and support further investigation of this antibody for cancer therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, death receptor-targeted therapies (e.g., DR4/DR5 agonist antibodies) were shown to enhance the antitumor activity of chemotherapy drugs (5-FU, irinotecan) in CRC xenograft models [145,146,147].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [146]
Citations
Cites
1 retracted
RETRACTED: Death-receptor activation halts clathrin-dependent endocytosis
Austin, C. D., Lawrence, D. A., Peden, A. A., Varfolomeev, E. E., Totpal, K., De Mazière, A. M., Klumperman, J., Arnott, D., Pham, V., Scheller, R. H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604044103 · Cited by 112 · cited 15×
“We used the phage display approach to develop a fully human, affinity-matured IgG1/l3 monoclonal antibody (called Apomab) that triggers apoptosis upon interaction with human DR5.”
ResultSelf-citationRetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Thornberry, N. A., & Lazebnik, Y. (1998) · Science · doi:10.1126/science.281.5381.1312 · Cited by 6,887 · cited 1×
“caspase-3, -6 and -7), which drive the apoptotic cell death program.(10,11) Two principal signaling pathways control cellular caspase activation: the intrinsic pathway is initiated”
BackgroundDeath Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866 · cited 1×
“these receptors can trigger apoptosis in various types of cancer cells, while sparing most normal cell types.(17,20) Two molecular types of proapoptotic receptor agonists (PARAs) that target”
BackgroundSelf-citation[19] Rapid and efficient site-specific mutagenesis without phenotypic selection
Kunkel, T. A., Roberts, J. D., & Zakour, R. A. (1987) · Methods in Enzymology · doi:10.1016/0076-6879(87)54085-x · Cited by 5,261
Nagata, S. (1997) · Cell · doi:10.1016/s0092-8674(00)81874-7 · Cited by 4,938
Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
Estimates of the cancer incidence and mortality in Europe in 2006
Ferlay, J., Autier, P., Boniol, M., Heanue, M., Colombet, M., & Boyle, P. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl498 · Cited by 4,036
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Cited by
Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy
von Karstedt, S., Montinaro, A., & Walczak, H. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.28 · Cited by 556
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
Ashkenazi, A. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2637 · Cited by 432
Self-citationTargeting the extrinsic apoptosis pathway in cancer
Ashkenazi, A. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.04.001 · Cited by 418
“Enhanced activity for this combination over either agent alone was observed as well in mice bearing LS180 or DLD-1 colon xenografts [29].”
BackgroundMethodInfluentialSelf-citationPhage display-derived human antibodies in clinical development and therapy
Frenzel, A., Schirrmann, T., & Hust, M. (2016) · mAbs · doi:10.1080/19420862.2016.1212149 · Cited by 346
“Drozitumab (Apomab, PRO95780, Roche/Genentech) was also generated by phage display from a human scFv library against TRAIL-R2.(137) A Phase 1 study demonstrated safety in humans at doses up to 20 mg/kg and evidence of activity in several different tumor types at 4 and 10 mg/kg.”
MethodInfluentialTo kill a tumor cell: the potential of proapoptotic receptor agonists
Ashkenazi, A., & Herbst, R. S. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34359 · Cited by 323
Self-citationOnto better TRAILs for cancer treatment
de Miguel, D., Lemke, J., Anel, A., Walczak, H., & Martinez-Lostao, L. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.174 · Cited by 304
“It should be noted that antibodies directed to TRAIL-DRs have a comparably long half-life in serum, whereas their in vivo activity is hampered by the fact that they require external cross-linking to induce effective TRAIL-DR clustering and, hence, TRAIL-DRmediated apoptosis.(130,131) To overcome these shortcomings and…”
BackgroundNoninvasive optical imaging of apoptosis by caspase-targeted activity-based probes
Edgington, L. E., Berger, A. B., Blum, G., Albrow, V. E., Paulick, M. G., Lineberry, N., & Bogyo, M. (2009) · Nature Medicine · doi:10.1038/nm.1938 · Cited by 276
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Alfaleh, M. A., Alsaab, H. O., Mahmoud, A. B., Alkayyal, A. A., Jones, M. L., Mahler, S. M., & Hashem, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01986 · Cited by 273
“PRO95780) IgG1-λ TRAIL-R2 (DR5) scFv (429) Genentech Oncology”
Wilson, N. S., Yang, B., Yang, A., Loeser, S., Marsters, S., Lawrence, D., Li, Y., Pitti, R., Totpal, K., Yee, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.012 · Cited by 248
“Indeed, drozitumab-induced caspase-3 activation and cell death in diverse cancer cell lines were augmented by crosslinking with an antihuman Fc-specific F(ab’)2 reagent (Figure 1C; see Figure S1A available online) (Adams et al., 2008).”
BackgroundMethodInfluentialSelf-citationTargeting the apoptosis pathway in hematologic malignancies
Zaman, S., Wang, R., & Gandhi, V. (2014) · Leukemia & Lymphoma · doi:10.3109/10428194.2013.855307 · Cited by 222
“TAS266 is a tetrameric DR5 targeted agonist that uses nanobody technology [122].”
InfluentialGong, Y., Bourhis, E., Chiu, C., Stawicki, S., DeAlmeida, V. I., Liu, B. Y., Phamluong, K., Cao, T. C., Carano, R. A. D., Ernst, J. A., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012682 · Cited by 206
“HT-1080 cells also display Apomab antibodyinduced apoptosis that is enhanced by Fc crosslinking (Figure S4) [26].”
Wang, S. (2008) · Oncogene · doi:10.1038/onc.2008.298 · Cited by 199
Activity-based probes: discovering new biology and new drug targets
Heal, W. P., Dang, T. H. T., & Tate, E. W. (2011) · Chem. Soc. Rev. · doi:10.1039/c0cs00004c · Cited by 193
Azijli, K., Weyhenmeyer, B., Peters, G. J., de Jong, S., & Kruyt, F. A. E. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2013.28 · Cited by 178
TNF-related apoptosis-inducing ligand (TRAIL): A new path to anti-cancer therapies
Holoch, P. A., & Griffith, T. S. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.06.066 · Cited by 178
“Apomab is another agonistic antibody that interacts with an epitope on TRAIL receptor-2 that partially overlaps with both regions of the TRAIL binding site, and is capable of inducing TRAIL receptor-2 clustering and apoptosis (Adams et al., 2008).”
BackgroundCamidge, D. R., Herbst, R. S., Gordon, M. S., Eckhardt, S. G., Kurzrock, R., Durbin, B., Ing, J., Tohnya, T. M., Sager, J., Ashkenazi, A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1267 · Cited by 169
“PRO95780 is a fully human, IgG1, monoclonal antibody that can trigger apoptosis through the extrinsic pathway through selective agonistic interaction with DR5.”
BackgroundInfluentialSelf-citationPlaying the DISC: Turning on TRAIL death receptor-mediated apoptosis in cancer
Pennarun, B., Meijer, A., de Vries, E. G. E., Kleibeuker, J. H., Kruyt, F., & de Jong, S. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.11.004 · Cited by 162
“Cross-linking of the anti-TRAIL-R2 antibodies was either required (TRA-8), or beneficial (HGS-ETR2 and Apomab) for their apoptotic effect in vitro [131,136,137].”
BackgroundTRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges
Bellail, A., Qi, L., Mulligan, P., Chhabra, V., & Hao, C. (2009) · Reviews on Recent Clinical Trials · doi:10.2174/157488709787047530 · Cited by 161
Death Receptor Agonists as a Targeted Therapy for Cancer
Wiezorek, J., Holland, P., & Graves, J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1692 · Cited by 160
Functional Imaging of Legumain in Cancer Using a New Quenched Activity-Based Probe
Edgington, L. E., Verdoes, M., Ortega, A., Withana, N. P., Lee, J., Syed, S., Bachmann, M. H., Blum, G., & Bogyo, M. (2013) · Journal of the American Chemical Society · doi:10.1021/ja307083b · Cited by 153
Forero, A., Shah, J. J., Wood, T. E., Posey, J. A., Carlisle, R. R., Copigneaux, C., Luo, F. M., Wojtowicz‐Praga, S., Percent, I. J., & Saleh, M. N. (2010) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0673 · Cited by 150
Fractional killing arises from cell‐to‐cell variability in overcoming a caspase activity threshold
Roux, J., Hafner, M., Bandara, S., Sims, J. J., Hudson, H., Chai, D., & Sorger, P. K. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145584 · Cited by 139
“It has previously been shown that the potency of anti-DR4/5 antibodies can be increased by cross-linking them with anti-Fc antibodies (Adams et al, 2008).”
Brünker, P., Wartha, K., Friess, T., Grau-Richards, S., Waldhauer, I., Koller, C. F., Weiser, B., Majety, M., Runza, V., Niu, H., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0647 · Cited by 137
“In vivo, and as demonstrated for drozitumab, a fully human DR5 agonistic antibody (8), this cross-linking activity is likely provided by activatory or inhibitory Fcg receptors (FcgR) on leukocytes in the tumor microenvironment (12, 13).”
BackgroundApoptosis Initiation Through the Cell-Extrinsic Pathway
Nair, P. M., Lu, M., Petersen, S., & Ashkenazi, A. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-417158-9.00005-4 · Cited by 154
“ptosis cascade, their binding to the target death receptors, and likely the receptor clustering that follows, is significantly altered from that of the natural ligand (Adams et al., 2008).”
BackgroundSelf-citationNovel Therapeutic Approaches in Chondrosarcoma
Polychronidou, G., Karavasilis, V., Pollack, S. M., Huang, P. H., Lee, A. P., & Jones, R. L. (2017) · Future Oncology · doi:10.2217/fon-2016-0226 · Cited by 134
Gieffers, C., Kluge, M., Merz, C., Sykora, J., Thiemann, M., Schaal, R., Fischer, C., Branschädel, M., Abhari, B. A., Hohenberger, P., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0323 · Cited by 114
“Our observation is in accordancewith published data on agonistic DR4/DR5-specific antibodies (7, 11, 22, 23) and confirms that cross-linking strongly potentiates the induction of apoptosis.”
BackgroundResultInfluentialHuet, H. A., Growney, J. D., Johnson, J. A., Li, J., Bilic, S., Ostrom, L., Zafari, M., Kowal, C., Yang, G., Royo, A., et al. (2014) · mAbs · doi:10.4161/19420862.2014.975099 · Cited by 108
Phage Display Libraries: From Binders to Targeted Drug Delivery and Human Therapeutics
Sioud, M. (2019) · Molecular Biotechnology · doi:10.1007/s12033-019-00156-8 · Cited by 114
Flusberg, D. A., Roux, J., Spencer, S. L., & Sorger, P. K. (2013) · Molecular Biology of the Cell · doi:10.1091/mbc.e12-10-0737 · Cited by 96
“We conclude that TRAIL and Fas induce a resistant state in surviving cells and that this state can be sustained by further TRAIL treatments even in the absence of cell death.”
BackgroundDeath receptor agonist therapies for cancer, which is the right TRAIL?
Holland, P. M. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.12.009 · Cited by 107
“Conatumumab, drozitumab, tigatuzumab, and lexatumumab are all monoclonal agonist antibodies selectively targeting DR5, whereas mapatumumab is a fully human agonist antibody against DR4 [42–47].”
BackgroundValley, C. C., Lewis, A. K., Mudaliar, D. J., Perlmutter, J. D., Braun, A. R., Karim, C. B., Thomas, D. D., Brody, J. R., & Sachs, J. N. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.306480 · Cited by 96
“Ligand-induced Dimerization Mediates DR5 Network Formation—It has been shown previously that TNF ligands (including TRAIL and a DR5 antibody agonist) induce receptor clustering within the plasmamembrane (37, 39, 40).”
BackgroundMethodInfluentialModeling pancreatic cancer in mice for experimental therapeutics
Mallya, K. B., Gautam, S. K., Aithal, A., Batra, S. K., & Jain, M. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188554 · Cited by 98
Chodorge, M., Züger, S., Stirnimann, C. U., Briand, C., Jermutus, L., Grütter, M. G., & Minter, R. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2011.208 · Cited by 92
Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox
Lim, B., Greer, Y. E., Lipkowitz, S., & Takebe, N. (2019) · Cancers · doi:10.3390/cancers11081087 · Cited by 90
“DR4-specific agonist mapatumumab [63,76–83], DR5-specific agonists drozitumab [64,65,84], conatumumab [66,67,85], lexatumumab [68,86–89], HGS-TR2J [90,91], tigatuzumab [69,92–96], and LBY135 [70] were all discontinued after phase 1 or 2 trials without impactful benefits despite their safety (Supplementary Table S1).”
BackgroundMechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
Apoptosis pathways and their therapeutic exploitation in pancreatic cancer
Fulda, S. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00748.x · Cited by 82
“Apomab, an agonistic antibody against TRAIL-R2, was recently reported to show antitumour activity against pancreatic cancer as single agent and also in combination with gemcitabine [42].”
BackgroundJohnson, G. E., Ivanov, V. N., & Hei, T. K. (2008) · APOPTOSIS · doi:10.1007/s10495-008-0212-y · Cited by 77
Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery
Fay, F., McLaughlin, K. M., Small, D. M., Fennell, D. A., Johnston, P. G., Longley, D. B., & Scott, C. J. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.07.065 · Cited by 69
“These findings are consistent with previous studies on DR5 activation, which have shown that DISC recruitment and subsequent procaspase 8 activation not only require ligand/receptor binding but also receptor clustering [41].”
ResultGreer, Y. E., Gilbert, S. F., Gril, B., Narwal, R., Brooks, D. L. P., Tice, D. A., Steeg, P. S., & Lipkowitz, S. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1116-1 · Cited by 68
Jin, H., Yang, R., Ross, J., Fong, S., Carano, R. A. D., Tótpál, K., Lawrence, D. A., Zheng, Z., Koeppen, H., Stern, H. M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0670 · Cited by 69
Self-citationHenrich, C. J., Brooks, A. D., Erickson, K. L., Thomas, C. L., Bokesch, H. R., Tewary, P., Thompson, C. R., Pompei, R. J., Gustafson, K. R., McMahon, J. B., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.38 · Cited by 64
Fox, N. L., Humphreys, R. C., Luster, T. A., Klein, J. L., & Gallant, G. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903319656 · Cited by 63
“chemotherapy in xenograft models, including those based on CRC, NSCLC, pancreatic, breast cancer and NHL cell lines [73-77].”
Backgroundvan Roosmalen, I. A. M., Quax, W. J., & Kruyt, F. A. E. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.08.010 · Cited by 62
“Target Reagent description Clinical status References DR4/5 Dulanermin (rhApo2L/TRAIL, AMG 951) rhTRAIL WT (residues 114-281) Phase I/II [65] DR4 2E12 Murine IgG1 mAb - [62] 4G7 Murine IgG2a mAb - [66] 4H6 Murine IgG1 mAb - [66] DR4-A Murine IgG mAb - [23] M270, M272 Murine IgG1 mAb - [67] M271, M273 Murine IgG2a mAb…”
BackgroundMultivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2–Induced Apoptosis
Swers, J. S., Grinberg, L., Wang, L., Feng, H., Lekstrom, K. J., Carrasco, R., Xiao, Z., Inigo, I. V., Leow, C. C., Wu, H., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1107 · Cited by 61
“activity in murine xenograft studies (7, 8, 39).”
BackgroundWajant, H. (2019) · Cancers · doi:10.3390/cancers11070954 · Cited by 60
“On the other side, the anti-TRAILR2 mAb Apomab, which is highly agonistic after crosslinking, showed no cytotoxic effects on human hepatocytes in vitro even if crosslinked [79].”
BackgroundVarfolomeev, E., Alicke, B., Elliott, J. M., Zobel, K., West, K., Wong, H., Scheer, J. M., Ashkenazi, A., Gould, S. E., Fairbrother, W. J., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.040139 · Cited by 57
Self-citationSreedhara, A., Lau, K. S. F., Li, C., Hosken, B. D., Macchi, F. D., Zhan, D., Shen, A. Y., Steinmann, D., Schöneich, C., & Lentz, Y. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300418r · Cited by 57
Zinonos, I., Labrinidis, A., Lee, M., Liapis, V., Hay, S. J., Ponomarev, V., Diamond, P., Zannettino, A. C. W., Findlay, D. M., & Evdokiou, A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0745 · Cited by 60
“platin, to inhibit tumor growth in lungs and improve survival (22, 23).”
BackgroundTargeted treatments in colorectal cancer: state of the art and future perspectives
Arnold, D., & Seufferlein, T. (2010) · Gut · doi:10.1136/gut.2009.196006 · Cited by 67
Phillips, D. C., Buchanan, F. G., Cheng, D., Solomon, L. R., Yu, X. H., Xue, J., Tahir, S. K., Smith, M. L., Zhang, H., Widomski, D. L., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2178 · Cited by 54
“Cancer Res; 81(12) June 15, 2021 CANCER RESEARCH 3404”
BackgroundMethodInfluentialWang, B. T., Kothambawala, T., Wang, L., Matthew, T. J., Calhoun, S. E., Saini, A. K., Kotturi, M. F., Hernandez, G., Humke, E. W., Peterson, M. S., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-1132 · Cited by 52
Therapeutic targeting of TRAIL death receptors
Cristofano, F. D., George, A., Tajiknia, V., Ghandali, M., Wu, L. J., Zhang, Y., Srinivasan, P. R., Strandberg, J., Hahn, M., Uruchurtu, A. S. S., et al. (2023) · Biochemical Society Transactions · doi:10.1042/bst20220098 · Cited by 54
Camidge, D. R. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.8.1167 · Cited by 49
“The best variant, comprised of two IgG1 VH and two lambda-3 VL chains, was named Apomab [14] .”
BackgroundInfluentialLima, C. M. R., Bayraktar, S., Flores, A. M., MacIntyre, J., Montero, A. J., Baranda, J. C., Wallmark, J. M., Portera, C. C., Raja, R. G., Stern, H. M., et al. (2012) · Cancer Investigation · doi:10.3109/07357907.2012.732163 · Cited by 47
“Cross-linking of drozitumab through its Fc region further augments its DR5-agonistic activity (6).”
BackgroundIvanov, V. N., & Hei, T. K. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0925-4 · Cited by 47
Kang, Z., Chen, J., Yu, Y., Li, B., Sun, S., Zhang, B., & Cao, L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2874 · Cited by 47
Meijer, A., Kruyt, F. A. E., van der Zee, A. G. J., Hollema, H., Le, P., ten Hoor, K. A., Groothuis, G. M. M., Quax, W. J., de Vries, E. G. E., & de Jong, S. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.636 · Cited by 47
“…agonistic antibodies and rhTRAIL variants have been generated to specifically target one TRAIL death receptor to enhance efficacy (Ichikawa et al, 2001; Kelley et al, 2005; Pukac et al, 2005; van der Sloot et al, 2006; Adams et al, 2008; Li et al, 2008; Tur et al, 2008; Reis et al, 2009, 2010).”
BackgroundSalzmann, S., Seher, A., Trebing, J., Weisenberger, D., Rosenthal, A., Siegmund, D., & Wajant, H. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.435917 · Cited by 45
“The human colorectal adenocarcinoma cell line HT29, HT1080 human fibrosarcoma cells, SKOV-3 human ovarian adenocarcinoma cells, Kym-1 human rhabdomyosarcoma cells, and HEK293 human embryonic kidney cells weremaintained in RPMI 1640medium (PAA Laboratories, Pasching, Germany), containing 10% FCS (30), and WiDr human co…”
MethodInfluentialRevisiting the Role of TRAIL/TRAIL-R in Cancer Biology and Therapy
Singh, D., Tewari, M., Singh, S., & Narayan, G. (2021) · Future Oncology · doi:10.2217/fon-2020-0727 · Cited by 43
Stern, H. M., Padilla, M., Wagner, K., Amler, L. C., & Ashkenazi, A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3108 · Cited by 45
Self-citationNaimi, A., Movassaghpour, A. A., Hagh, M. F., Talebi, M., Entezari, A., Jadidi‐Niaragh, F., & Solali, S. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.12.082 · Cited by 45
Monoclonal Antibodies in the Treatment of Pancreatic Cancer
Huang, Z., & Buchsbaum, D. J. (2009) · Immunotherapy · doi:10.2217/1750743x.1.2.223 · Cited by 44
Kundu, M., Greer, Y. E., Dine, J. L., & Lipkowitz, S. (2022) · Cells · doi:10.3390/cells11233717 · Cited by 41
Apo2L/TRAIL Inhibits Tumor Growth and Bone Destruction in a Murine Model of Multiple Myeloma
Labrinidis, A., Diamond, P., Martin, S. K., Hay, S. J., Liapis, V., Zinonos, I., Sims, N. A., Atkins, G. J., Vincent, C., Ponomarev, V., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2444 · Cited by 34
El‐Mesery, M., Trebing, J., Schäfer, V., Weisenberger, D., Siegmund, D., & Wajant, H. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.402 · Cited by 32
“The need of supramolecular clustering might also explain the finding that oligomerized and FcgR-bound TRAILR2-specific antibodies display enhanced signaling capabilities.(7,19,20) Thus, TRAIL death receptor-targeting antibodies might elicit in vivo suboptimal receptor stimulation as long as they are not oligomerized b…”
BackgroundTRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2
Tamada, T., Shinmi, D., Ikeda, M., Yonezawa, Y., Kataoka, S., Kuroki, R., Mori, E., & Motoki, K. (2015) · Scientific Reports · doi:10.1038/srep17936 · Cited by 33
“In contrast, epitope recognition by BDF1 and YSd1, which have little or no agonistic activity 19 , predominantly overlapped in CRD1 and CRD2 with that by KMTR2 (Fig.”
Wang, Y., Guo, S., Li, D., Tang, Y., Li, L., Su, L., & Liu, X. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2436-x · Cited by 28
Cristofanon, S., Abhari, B. A., Krueger, M. A., Tchoghandjian, A., Momma, S., Calaminus, C., Vucic, D., Pichler, B. J., & Fulda, S. (2015) · Cell Death and Disease · doi:10.1038/cddis.2014.592 · Cited by 27
“As glioblastoma cell lines predominately express TRAILR2, we selected a human monoclonal antibody specifically directed against TRAIL-R2 (Drozitumab) to target the TRAIL signaling pathway.(19) To antagonize IAP proteins, we used the bivalent Smac mimetic BV6.”
MethodMolecular Targeted Approaches for Treatment of Pancreatic Cancer
Huang, Z. Q., Saluja, A. K., Dudeja, V., Vickers, S. M., & Buchsbaum, D. J. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796957427 · Cited by 46
Picarda, G. G. A., Trichet, V., Télétchéa, S., Heymann, D., & Rédiní, F. (2012) · Europe PMC (PubMed Central) · Cited by 30
Liu, Y., Hawkins, O. E., Vilgelm, A. E., Pawlikowski, J. S., Ecsedy, J., Sosman, J. A., Kelley, M. C., & Richmond, A. J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0293 · Cited by 29
“To overcome the short half-life of Apo2L/TRAIL, several specific death receptor agonist antibodies that have a long half-life were developed (45).”
BackgroundLipid- and polyion complex-based micelles as agonist platforms for TNFR superfamily receptors
Gilbreth, R. N., Novarra, S., Wetzel, L. K., Florinas, S., Cabral, H., Kataoka, K., Rios‐Doria, J., Christie, R. J., & Baca, M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.041 · Cited by 25
TRAIL-R1 and TRAIL-R2 Mediate TRAIL-Dependent Apoptosis in Activated Primary Human B Lymphocytes
Staniek, J., Lorenzetti, R., Heller, B., Janowska, I., Schneider, P., Unger, S., Warnatz, K., Seidl, M., Venhoff, N., Thiel, J., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00951 · Cited by 28
“Even though, to date, recombinant forms of TRAIL, and agonistic antibodies against TRAIL-R1 and TRAIL-R2 have failed to provide clinical benefit in cancer patients, novel cross-linking agonistic TRAIL-R antibodies are currently under evaluation (76, 77) and different approaches have been undertaken to re-sensitize tra…”
BackgroundJazirehi, A. R., Kurdistani, S. K., & Economou, J. S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302532 · Cited by 25
TRAIL-Based Therapy in Pediatric Bone Tumors: How to Overcome Resistance
Guiho, R., Biteau, K., Heymann, D., & Rédiní, F. (2015) · Future Oncology · doi:10.2217/fon.14.293 · Cited by 24
Dine, J. L., O'Sullivan, C. C., Voeller, D. M., Greer, Y. E., Chavez, K. J., Conway, C. M., Sinclair, S., Stone, B., Amiri‐Kordestani, L., Merchant, A. S., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3673-z · Cited by 23
Mondal, T., Gaur, H., Wamba, B. E. N., Michalak, A. G., Stout, C., Watson, M. R., Aleixo, S. L., Singh, A. N., Condello, S., Faller, R., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01229-7 · Cited by 23
“On the other hand, FasL E163A , FasL E271A , FasL ED163-164AA , and FasL EE270-271AA mutants lost both binding (S3b,c), apoptotic cytotoxicity, and Fas clustering activity against tumor and T cells (Fig.”
BackgroundInfluentialPiechocki, M. P., Wu, G. S., Jones, R. F., Jacob, J. B., Gibson, H. M., Ethier, S. P., Abrams, J., Yagita∥, H., Venuprasad, K., & Wei, W. Z. (2012) · International Journal of Cancer · doi:10.1002/ijc.27534 · Cited by 21
“Crosslinking of the DR5-binding mAb by secondary antibody or FccR-bearing cells has been shown to result in receptor clustering and amplified apoptotic signal and may enhance tumor cell apoptosis in vivo.(28) To test if crosslinking of DR5 antibodies enhanced tumor cell apoptosis, SUM159 cells coated for 30 min with i…”
TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cellsin vitroandin vivo
Piao, X., Ozawa, T., Hamana, H., Shitaoka, K., Jin, A., Kishi, H., & Muraguchi, A. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1131380 · Cited by 21
“TRAIL-R1 or R2 antibodies and different chemotherapeutics resulted in enhanced cell killing in vitro compared to antibodies or chemotherapeutics alone.(22-25,28,51,52) The enhanced cell”
BackgroundEdgington‐Mitchell, L. E., & Bogyo, M. S. (2013) · Current Protocols in Chemical Biology · doi:10.1002/9780470559277.ch120235 · Cited by 20
“Representative Protocol: Imaging Anti-DR5–Induced Caspase Activity with ABPs This model has been optimized for imaging caspase activity using ABPs (Adams et al., 2008; Edgington et al., 2009, 2012).”
MethodWaight, J. D., Gombos, R. B., & Wilson, N. S. (2017) · Human Antibodies · doi:10.3233/hab-160308 · Cited by 23
“…with this observation, other TNFR agonist antibodies shown to mediate downstream signaling via a bivalent interaction alone are reported to bind to the receptor within or near the ligand binding site, likely mimicking properties of ligand co-engagement and promoting receptor clustering [1,137].”
Advances in the study of death receptor 5
Qiao, X., Guo, S., Meng, Z., Gan, H. K., Wu, Z., Sun, Y., Liu, S., Dou, G., & Gu, R. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1549808 · Cited by 19
Death Receptor 5 Networks Require Membrane Cholesterol for Proper Structure and Function
Lewis, A. K., Valley, C. C., Peery, S. L., Brummel, B. E., Braun, A. R., Karim, C. B., & Sachs, J. N. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.10.001 · Cited by 18
Lee, S., Park, D.-W., Sung, E.-S., Park, H., Kim, J., & Kim, Y. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.09.041 · Cited by 17
Eng, J. W. ‐., Mace, T. A., Sharma, R. B., Twum, D. Y. F., Peng, P., Gibbs, J. F., Pitoniak, R., Reed, C. B., Abrams, S. I., Repasky, E. A., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0136-y · Cited by 17
“In this study, we found that the anti-DR5 antibody, dro-zitumab (see [19] for details of this antibody), used alone, inhibits the growth of pancreatic cancer patient xenografts.”
BackgroundDu, G., Zhao, L., Zheng, Y., Belfetmi, A., Cai, T., Xu, B., Heyninck, K., Heede, K. V. D., Buyse, M.-A., Fontana, P., et al. (2023) · Cell Research · doi:10.1038/s41422-022-00755-2 · Cited by 16
Weber, T. G., Pöschinger, T., Galbán, S., Rehemtulla, A., & Scheuer, W. (2013) · Neoplasia · doi:10.1593/neo.13932 · Cited by 17
“, drozitumab that is a human agonistic antibody to DR5 and directly induces apoptosis by DR5 clustering through the extrinsic pathway [9,10].”
BackgroundMeasurement of conatumumab‐induced apoptotic activity in tumors by fine needle aspirate sampling
Zoog, S. J., Ma, C. Y., Kaplan‐Lefko, P. J., Hawkins, J. M., Moriguchi, J., Zhou, L., Pan, Y., Hsu, C., Friberg, G., Herbst, R. S., et al. (2010) · Cytometry Part A · doi:10.1002/cyto.a.20940 · Cited by 16
Lee, C., Park, K.-J., Kim, S. J., Kwon, O., Jeong, K. J., Kim, A., & Kim, Y. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.05.040 · Cited by 15
Milutinovic, S., Kashyap, A. K., Yanagi, T., Wimer, C. D., Zhou, S., O’Neil, R. E., Kurtzman, A. L., Faynboym, A., Xu, L., Hannum, C. H., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0400 · Cited by 15
“Furthermore, synergistic combinationswith other anticancer agents, such as that demonstrated with AEG40730 and bortezomib may additionally expand the overall clinical utility into patient populations where death receptor activation alone is insufficient to cause tumor cell death.”
BackgroundMethodResultInfluentialNoonan, J., Jarzabek, M. A., Lincoln, F. A., Cavanagh, B., Pariag, A. R., Jurić, V., Young, L. S., Ligon, K. L., Jahns, H., Zheleva, D. I., et al. (2019) · Cancers · doi:10.3390/cancers11122005 · Cited by 15
“To target the TRAIL signaling pathway, we selected a monoclonal antibody specifically directed against human TRAIL-R2 (drozitumab) [32], as GBM cell lines predominately express TRAIL-R2 [33].”
BackgroundPhage display for discovery of anticancer antibodies
Istomina, P. V., Gorchakov, A. A., Paoin, C., & Yamabhai, M. (2024) · New Biotechnology · doi:10.1016/j.nbt.2024.08.506 · Cited by 15
Reddy, A., Growney, J. D., Wilson, N. S., Emery, C. M., Johnson, J. A., Ward, R., Monaco, K., Korn, J. M., Monahan, J. E., Stump, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138486 · Cited by 14
“To date, DR5 targeting efforts have focused primarily on bivalent antibodies which depend on secondary Fc-mediated crosslinking for activity by immune cells [7 – 9].”
Xiang, H., Reyes, A. E., Eppler, S., Kelley, S. K., & Damico‐Beyer, L. A. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2200-3 · Cited by 14
Satta, A., Mezzanzanica, D., Caroli, F., Frigerio, B., Nicola, M. D., Kontermann, R. E., Iacovelli, F., Desideri, A., Anichini, A., Canevari, S., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1494105 · Cited by 11
Picarda, G. G. A., Surget, S., Guiho, R., Télétchéa, S., Berreur, M., Tirode, F., Pellat‐Deceunynck, C., Heymann, D., Trichet, V., & Rédiní, F. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0390 · Cited by 13
“Several Phase 1 and 2 studies targeting DR4 (Mapatumumab, TRM-1) or DR5 (Lexatumumab) are carried out in patients with solid malignancies, associated or not to chemotherapy (18-22).”
BackgroundLei, G., Xu, M., Xu, Z., Gu, L., Lü, C., Bai, Z., Wang, Y., Zhang, Y., Hu, H., Jiang, Y., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102064 · Cited by 11
“Consistent with previous research of crystallographic analysis of the Apomab–DR5 Complex [31], the CRD3 domain may be important for DR5 activation.”
ResultActivating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma
Kang, Z., Sun, S., & Cao, L. (2012) · ISRN Oncology · doi:10.5402/2012/395952 · Cited by 10
“In the absence of the cross-linking, most DR5 therapeutic antibodies exhibited low to minimal activity in vitro against target tumor cells [95–98].”
BackgroundCrystal structure of CD27 in complex with a neutralizing noncompeting antibody
Teplyakov, A., Obmolova, G., Malia, T., & Gilliland, G. L. (2017) · Acta Crystallographica Section F Structural Biology Communications · doi:10.1107/s2053230x17005957 · Cited by 12
“Typically, they bind around CRD1 and CRD2 on the side of the receptor molecule (Fellouse et al., 2005; Li et al., 2006; Adams et al., 2008; Chodorge et al., 2012; Graves et al., 2014; Tamada et al., 2015; Yamniuk et al., 2016).”
BackgroundZinonos, I., Labrinidis, A., Liapis, V., Hay, S. J., Panagopoulos, V., DeNichilo, M. O., Ponomarev, V., Ingman, W. V., Atkins, G. J., Findlay, D. M., et al. (2014) · PubMed · Cited by 11
Metadata
- Authors
- Adams, C., Totpal, K., Lawrence, D., Marsters, S., Pitti, R., Yee, S., Ross, S., Deforge, L., Koeppen, H., Sagolla, M., Compaan, D., Lowman, H., Hymowitz, S., & Ashkenazi, A.
- Affiliations
- Genentech (US)
- Corresponding author
- Ashkenazi, A
- Venue
- Cell Death & Differentiation
- Published
- 2008-01-25
- Volume
- 15
- Issue
- 4
- Pages
- 751-761
- ISSN
- 1350-9047 (ISSN-L)
- 1476-5403
- OpenAlex
- W2074106785
- Cited by
- 148
- References
- 51
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 2 · 2023: 7 · 2022: 1 · 2021: 8 · 2020: 5 · 2019: 6 · 2018: 4 · 2017: 9 · 2016: 9 · 2015: 11 · 2014: 7 · 2013: 19 · 2012: 12
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cell Death and Differentiation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- DR5, agonistic monoclonal antibody, antigen-antibody reaction, extrinsic apoptotic pathway, TRAIL receptors, FADD, caspase-8, receptor clustering, selective cytotoxicity, anticancer activity, colorectal cancer, non-small cell lung cancer, pancreatic cancer
- MeSH terms
- Animals, Antibodies, Monoclonal, Antibody Affinity, Antibody Specificity, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Binding Sites, Antibody, Dose-Response Relationship, Drug, Female, Humans, Mice, Nude, Models, Molecular, Neoplasms, Experimental, Protein Binding, Protein Conformation, Receptor Aggregation, Time Factors, Signal Transduction, Apoptosis, Crystallography, X-Ray, Epitope Mapping, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Caspase 8, Fas-Associated Death Domain Protein, Receptors, TNF-Related Apoptosis-Inducing Ligand
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.